MedTrace Logo

Glucocorticoids and Pulmonary Hypertension

NCT04499196 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-03-31

No results posted yet for this study

Summary

Pediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever expanding body of knowledge indicates the important contribution of inflammation to pathogenesis and successful treatment with glucocorticoids. Over the last several years the investigators have utilized steroids in patients with severe pulmonary hypertension as part of a treatment regimen. These basic science studies possibly identifies a biochemical etiology for the development of disease and may also be impacted by the administration of steroids. Additionally, there is a commercially available assay which tests for all of the above molecules.

Conditions

  • Pulmonary Hypertension Due to Lung Diseases and Hypoxia
  • Pulmonary Hypertension
  • Bronchopulmonary Dysplasia

Interventions

DRUG

GlucoCorticoid

Administering glucocorticoid

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Eligibility

Min Age
1 Day
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-29
Primary Completion
2022-07-29
Completion
2022-07-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499196 on ClinicalTrials.gov